Abstract: The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.

Abstract: Crystalline polymorphic forms of a compound of formula N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide are described. The two polymorphic forms, named polymorphic Form A and polymorphic Form B, can be used in the treatment of drug addiction and alcoholism and have very good stability. Methods for preparing the polymorphic forms are also described.

Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.

Abstract: The present invention relates to a method of removing undifferentiated stem cells and dedifferentiated stem cells from a sample of cells. The invention further relates to preventing dedifferentiation of differentiated cells. Both methods comprise of administering to said cells an effective amount of compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, n, p, Z and T are defined herein.

Abstract: Methods of using certain ?-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Abstract: System, including methods compositions, and kits, for controlling the growth of fungi and other pathogens in plants using at least one alkamide, which may function by increasing or eliciting natural defense mechanisms of the plants against such pathogens.

Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.

Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.

Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.

Abstract: The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.

Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.

Abstract: A stack of folded web substrates is disclosed. Each folded web substrate has a folded surface area of about A/8 produced from a respective unfolded web substrate having an unfolded surface area of A and having a lotion applied to one surface thereof. The stack of folded web substrates has a normalized Mellin gauge value of greater than 0.06.

Abstract: Exemplary embodiments of the present invention relate to pesticides, insecticides, insect repellant, insect anti-feeding, cleaning, glue dissolving and anti-irritation and wound healing compositions for humans and animals and, more particularly, to such compositions which are effective in killing, removing and/or repelling a wide range of endoparasites, ectoparasites and insects while also being non-toxic to humans, animals, and the environment. An exemplary embodiment of the present invention is directed to an aqueous composition including a mixture of at least one ethanolamide and at least one esterified fatty acid. Another exemplary embodiment of the present invention is directed to an aqueous composition including at least one esterified fatty acid in water and at least one emulsifier. The aqueous compositions may be used as a cleaning composition, insecticide, insect repellant, glue solvent or to relieve irritation from and/or promote healing of insect bites, skin abrasions superficial burns and wounds.

Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.

Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.

Abstract: A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.

Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.

Abstract: This invention provides a composition comprising Formula I, or salt thereof, wherein X is either chlorine or bromine, Y is either hydrogen or an alkyl group having a carbon chain length from 1 to 5 carbon atoms, and R is an alkyl group having a carbon chain length from 1 to 5 carbon atoms, except that X is not chlorine when Y is hydrogen and R is an ethyl group. A method of preventing bone erosion in a patient and a method of reducing inflammation in a patient using the compositions of Formula I are disclosed.

Abstract: The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.

Abstract: System, including methods compositions, and kits, for controlling the growth of fungi and other pathogens in plants using at least one alkamide, which may function by increasing or eliciting natural defense mechanisms of the plants against such pathogens.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: Methods of using certain a-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Abstract: Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds and methods of their use.

Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.

Abstract: The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can be in patches, suppositories, ovules, pessaries, aerosol or spray, emulsions, suspensions, solutions.

Abstract: There is described primarily N-nonanoylvanillylamine for use in a therapeutic method as (a) an agent for reducing the appetite and/or (b) an agent for imparting a feeling of fullness and/or (c) a mood enhancer, as well as the non-therapeutic use of N-nonanoylvanillylamine as (a) an agent for reducing the appetite and/or (b) an agent for imparting a feeling of fullness and/or (c) a mood enhancer. The non-therapeutic use of corresponding substance mixtures is also further described. Finally, the invention relates also to orally consumable products (in particular foodstuffs, feeds and medicaments) comprising N-nonanoylvanillylamine, wherein the N-nonanoylvanillylamine is present in a concentration that (a) reduces the appetite and/or (b) brings about a feeling of fullness and/or (c) enhances the mood, but which concentration is low.

Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Abstract: The invention relates to a medicinal product which is free from sympathomimetics, has an advantageous effect on the nasal mucosa in case of common colds, hay fever, dry nose and sympathomimetic dependencies, and is provided in the form of a nasal spray, a nasal douche or nasal drops.

Abstract: The invention provides a novel aqueous composition for the storage and preservation of transplants, such as organ or tissue allografts. The composition comprises the compound N-octanoyl dopamine in solubilised form. The composition may also be administered as a pre-treatment of transplant donors. Moreover, it may be used in transplant recipients, optionally in combination with immunosuppressants.

Abstract: The disclosure herein provides the compounds of Formulas 1, 2 and 3 and their pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, and/or injection. Such compositions may be used for the treatment of metabolic conditions, cystinosis, non-alcoholic Steatohepatitis, hypertriglyceridemia, and/or neurodegenerative disorders, and/or their associated complications.

Abstract: Provided is a composition including, as an active ingredient, at least one selected from the group consisting of amines, amides and polyols. The cosmetic composition has an effect of preventing aging and may be applied in various industrial fields, including cosmetics.

Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.

Abstract: The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided.

Abstract: A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided comprising [A] one or more undecylenic acid derivatives depicted by Formula (I), [B] one or more octanoic acid derivatives depicted by Formula (II), and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two ‘liquid alcohol ethers’; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the ‘liquid alcohol ether’, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.

Abstract: A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer; a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer; and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation.

Abstract: Suggested are biocide compositions, comprising (a) at least one dialkylamide based on a hydroxycarboxylic acid, and (b) at least one biocide. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.

Abstract: Compounds of formula (I) wherein R1-R5, n and m have the same meaning as given in the description, having cooling properties are disclosed. Furthermore a process of their production and consumer products comprising them are disclosed.

Abstract: Suggested are biocide compositions, comprising (a) Valerolactone and/or its amide derivatives; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show high solubility for biocides and improved emulsification properties.

Abstract: A water-based cosmetic that includes: (A) ceramidic compound-containing particles that include a ceramidic compound and that are dispersed as an oil phase in an aqueous phase; (B) a fatty acid component composed of at least one selected from the group consisting of fatty acids and fatty acid salts; and (C) a polyhydric alcohol component that includes a first polyhydric alcohol having an IOB of 2.2 or more and a total content in the composition of from 3% by mass to 20% by mass, and a second polyhydric alcohol having an IOB of 2.0 or less and a total content in the composition of 0% by mass or not more than 3% by mass, wherein a total content of surfactant in the composition is 0% by mass or not more than 1% by mass, and a total mass of ceramidic compound in the composition is at least 3.0 times a total mass of the fatty acid component in the composition.

Abstract: The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5 to 7 ring members; R5 representing a hydrogen atom or a (C1-C3) alkyl group; R6 representing a hydrogen atom or a (C1-C4) alkyl group; R3 represents a hydrogen atom or a (C1-C6) alkyl-group, or —OR3 represents a phosphate group; it being possible for the two groups R3 to form, together, an isopropylidene group; R4 represents a hydrogen atom or —OR4 represents a-phosphate group; and the salts, solvates and isomers thereof. The invention also relates to a cosmetic composition comprising a compound (I) and the corresponding new compounds.

Abstract: This invention relates to ophthalmic disinfecting and preserving compositions. More particularly, this invention relates to multi-purpose disinfecting solutions [MPDS] suitable for use in or with storage cases for treating multiple-use contact lenses and/or for preserving, disinfecting or packaging of contact and other ophthalmic lenses.

Abstract: The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation.

Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.

Abstract: Nose ointment for the prophylaxis of inhalation allergic reactions comprising at least one mixture of saturated hydrocarbons characterized in that the at least one mixture of saturated hydrocarbons has a viscosity by the DIN 51 562 method of >6 mm2/s (100° C.).

Abstract: The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.

Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.

Abstract: An object of the present invention is to provide an antithrombotic agent that has fewer side effects and that is highly effective. The present invention provides an antithrombotic agent comprising (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by Formula (1) as an active ingredient.